Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Bipolar Disorder (Manic Depression)-Pipeline Review, H1 2015

Bipolar Disorder (Manic Depression)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Bipolar Disorder (Manic Depression)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Bipolar Disorder (Manic Depression)-Pipeline Review, H1 2015', provides an overview of the Bipolar Disorder (Manic Depression)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Bipolar Disorder (Manic Depression) Overview 10

Therapeutics Development 11

Pipeline Products for Bipolar Disorder (Manic Depression)-Overview 11

Pipeline Products for Bipolar Disorder (Manic Depression)-Comparative Analysis 12

Bipolar Disorder (Manic Depression)-Therapeutics under Development by Companies 13

Bipolar Disorder (Manic Depression)-Therapeutics under Investigation by Universities/Institutes 15

Bipolar Disorder (Manic Depression)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Bipolar Disorder (Manic Depression)-Products under Development by Companies 19

Bipolar Disorder (Manic Depression)-Products under Investigation by Universities/Institutes 22

Bipolar Disorder (Manic Depression)-Companies Involved in Therapeutics Development 23

Ascendis Pharma A/S 23

AstraZeneca PLC 24

Convergence Pharmaceuticals Ltd. 25

D-Pharm Ltd. 26

Delpor, Inc. 27

Eli Lilly and Company 28

Intas Pharmaceuticals Ltd. 29

Intra-Cellular Therapies, Inc. 30

KemPharm, Inc. 31

MarcoPolo Pharmaceuticals SA 32

Navigen Pharmaceuticals, Inc. 33

Neurocrine Biosciences, Inc. 34

Omeros Corporation 35

Otsuka Holdings Co., Ltd. 36

Pfizer Inc. 37

Reviva Pharmaceuticals Inc. 38

Richter Gedeon Nyrt. 39

SK Biopharmaceuticals Co., Ltd. 40

Sumitomo Dainippon Pharma Co., Ltd. 41

Takeda Pharmaceutical Company Limited 42

Teva Pharmaceutical Industries Limited 43

Zogenix, Inc. 44

Zysis Limited 45

Bipolar Disorder (Manic Depression)-Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Target 47

Assessment by Mechanism of Action 49

Assessment by Route of Administration 51

Assessment by Molecule Type 53

Drug Profiles 55

ACP-005-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

aripiprazole-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

aripiprazole-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

aripiprazole CR-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

BRDK-98958073-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

cariprazine-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

CNV-1061436-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

DP-VPA-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Drug for Bipolar Disorder-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Drug for Cancer and Neurodegenerative Disease-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Endoxifen-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

ITI-007-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

KP-303-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

lurasidone hydrochloride-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

LY-2979165-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

NP-202-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

paliperidone palmitate-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

PGW-5-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

quetiapine fumarate ER-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

ramelteon-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

risperidone-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

risperidone-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

RP-5063-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

SKL-PSY-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Small Molecule to Target GPR50 for CNS and Metabolic Disorders-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Synthetic Peptides to Inhibit IMPase for Bipolar Disorder-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

uridine triacetate-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

ziprasidone hydrochloride-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Bipolar Disorder (Manic Depression)-Recent Pipeline Updates 94

Bipolar Disorder (Manic Depression)-Dormant Projects 113

Bipolar Disorder (Manic Depression)-Dormant Projects 113

Bipolar Disorder (Manic Depression)-Discontinued Products 116

Bipolar Disorder (Manic Depression)-Product Development Milestones 117

Featured News & Press Releases 117

May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole 117

Mar 30, 2015: Sunovion Pharmaceuticals Europe to Present New Data on LATUDA (lurasidone) at the 23rd European Congress of Psychiatry 117

Jan 14, 2015: Sunovion Pharmaceuticals Files Patent Infringement Lawsuits Regarding Latuda 118

Jan 13, 2015: Germany's Federal Court Invalidates AstraZeneca's Patent On Seroquel XR 119

Apr 03, 2014: Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression 119

Mar 31, 2014: Forest Laboratories and Gedeon Richter Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression 119

Nov 13, 2013: Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly 121

Nov 01, 2013: Sunovion Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry 121

Oct 29, 2013: A Phase I ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidates 123

Jun 28, 2013: Sunovion Pharmaceuticals Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression 124

Appendix 127

Methodology 127

Coverage 127

Secondary Research 127

Primary Research 127

Expert Panel Validation 127

Contact Us 127

Disclaimer 128

List of Tables

Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2015 11

Number of Products under Development for Bipolar Disorder (Manic Depression)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Development by Companies, H1 2015 (Contd..2) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Bipolar Disorder (Manic Depression)-Pipeline by Ascendis Pharma A/S, H1 2015 23

Bipolar Disorder (Manic Depression)-Pipeline by AstraZeneca PLC, H1 2015 24

Bipolar Disorder (Manic Depression)-Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 25

Bipolar Disorder (Manic Depression)-Pipeline by D-Pharm Ltd., H1 2015 26

Bipolar Disorder (Manic Depression)-Pipeline by Delpor, Inc., H1 2015 27

Bipolar Disorder (Manic Depression)-Pipeline by Eli Lilly and Company, H1 2015 28

Bipolar Disorder (Manic Depression)-Pipeline by Intas Pharmaceuticals Ltd., H1 2015 29

Bipolar Disorder (Manic Depression)-Pipeline by Intra-Cellular Therapies, Inc., H1 2015 30

Bipolar Disorder (Manic Depression)-Pipeline by KemPharm, Inc., H1 2015 31

Bipolar Disorder (Manic Depression)-Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015 32

Bipolar Disorder (Manic Depression)-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 33

Bipolar Disorder (Manic Depression)-Pipeline by Neurocrine Biosciences, Inc., H1 2015 34

Bipolar Disorder (Manic Depression)-Pipeline by Omeros Corporation, H1 2015 35

Bipolar Disorder (Manic Depression)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 36

Bipolar Disorder (Manic Depression)-Pipeline by Pfizer Inc., H1 2015 37

Bipolar Disorder (Manic Depression)-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 38

Bipolar Disorder (Manic Depression)-Pipeline by Richter Gedeon Nyrt., H1 2015 39

Bipolar Disorder (Manic Depression)-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 40

Bipolar Disorder (Manic Depression)-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 41

Bipolar Disorder (Manic Depression)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 42

Bipolar Disorder (Manic Depression)-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 43

Bipolar Disorder (Manic Depression)-Pipeline by Zogenix, Inc., H1 2015 44

Bipolar Disorder (Manic Depression)-Pipeline by Zysis Limited, H1 2015 45

Assessment by Monotherapy Products, H1 2015 46

Number of Products by Stage and Target, H1 2015 48

Number of Products by Stage and Mechanism of Action, H1 2015 50

Number of Products by Stage and Route of Administration, H1 2015 52

Number of Products by Stage and Molecule Type, H1 2015 54

Bipolar Disorder (Manic Depression) Therapeutics-Recent Pipeline Updates, H1 2015 94

Bipolar Disorder (Manic Depression)-Dormant Projects, H1 2015 113

Bipolar Disorder (Manic Depression)-Dormant Projects (Contd..1), H1 2015 114

Bipolar Disorder (Manic Depression)-Dormant Projects (Contd..2), H1 2015 115

Bipolar Disorder (Manic Depression)-Discontinued Products, H1 2015 116

List of Figures

Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2015 11

Number of Products under Development for Bipolar Disorder (Manic Depression)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 46

Number of Products by Top 10 Targets, H1 2015 47

Number of Products by Stage and Top 10 Targets, H1 2015 47

Number of Products by Top 10 Mechanism of Actions, H1 2015 49

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 49

Number of Products by Top 10 Routes of Administration, H1 2015 51

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 52

Number of Products by Top 10 Molecule Types, H1 2015 53

Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ascendis Pharma A/S

AstraZeneca PLC

Convergence Pharmaceuticals Ltd.

D-Pharm Ltd.

Delpor, Inc.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

Intra-Cellular Therapies, Inc.

KemPharm, Inc.

MarcoPolo Pharmaceuticals SA

Navigen Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

SK Biopharmaceuticals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Limited

Zogenix, Inc.

Zysis Limited

Bipolar Disorder (Manic Depression) Therapeutic Products under Development, Key Players in Bipolar Disorder (Manic Depression) Therapeutics, Bipolar Disorder (Manic Depression) Pipeline Overview, Bipolar Disorder (Manic Depression) Pipeline, Bipolar Disorder (Manic Depression) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com